期刊文献+

白藜芦醇对腹膜透析液作用下人腹膜间皮细胞线粒体活性氧产生的影响

Effect of Resveratrol of Reactive Oxygen Species in Human Peritoneal Mesothelial Cells Exposed to Glucose-based Peritoneal Dialysis
下载PDF
导出
摘要 目的白藜芦醇对腹膜透析液作用下人腹膜间皮细胞线粒体活性氧产生的影响。方法体外培养人腹膜间皮细胞株第5~10代(HMrSV5,DMEM/F12培养基含10%胎牛血清)用于实验研究。MTT检测细胞活力。实验分组:阴性对照组(培养基)、阳性对照组(加入Rotenone,细胞线粒体呼吸链酶复合体I抑制剂)、实验组(1.5%葡萄糖腹膜透析液)、丁预组(白藜芦醇+1.5%葡萄糖腹膜透析液)。流式细胞仪检测总线粒体、呼吸性线粒体、产活性氧线粒体。结果与阴性对照组比较,实验组总线粒体、产活性氧线粒体增加,差异具有统计学意义。与实验组比较,干预组总线粒体、产活性氧线粒体减少,差异具有统计学意义。结论白藜芦醇可降低含葡萄糖腹膜透析液作用人腹膜间皮细胞后活性氧的产生。 Objective To explore the effect of resveratrol of reactive oxygen species in human peritoneal mesothelial cells exposed to glucose- based peritoneal dialysis. Methods Cells (SV40 immortalized human peritoneal mesothelial cell line) were grown in type ] collagen - coated dishes in DMEM/F12 containing 10% FCS. All experiments on immortalized mesothelial cells were performed from pas- sages 5 to 10. Cell viability was assessed using MTT. Cells were divided into 4 groups: negative control (medium) , positive control ( Ro- tenone) , 1.5% glucose -based peritoneal dialysis, resveratrol plus 1.5% glucose- based peritoneal dialysis. Flow cytometric was used to analyze the Mitotracker deep red,Mitotraeker green and MitoSOX. Results Compared to the negative control, Mitotracker green and MitoSOX were significantly increased in the cells exposed to 1.5% glucose -based peritoneal dialysis. In addition, Mitotracker green and MitoSOX were significantly decreased in the cells exposed to resveratrol plus 1.5% glucose - based peritoneal dialysis compared to the cells exposed to 1.5% glucose - based peritoneal dialysis only. Conclusioll Resveratrol can reduce the reactive oxygen species in human peritoneal mesothelial cells exposed to glucose -based peritoneal dialysis.
出处 《医学研究杂志》 2013年第11期43-46,共4页 Journal of Medical Research
基金 国家自然科学基金资助项目(81200555) 广东省自然科学基金资助项目(S2011040002796) 广东省中医药局建设中医药强省科研课题(20122042)
关键词 白藜芦醇 人腹膜间皮细胞 活性氧 Resveratrol Human peritoneal mesothelial cells Reactive oxygen species
  • 相关文献

参考文献14

  • 1Li PK,Chow KM.Peritoneal dialysis-first policy made successful:perspectives and actions[J].Am J Kidney Dis,2013,[Epub ahead of print].
  • 2伍军,阳晓,余学清.腹膜透析与血液透析:哪种透析治疗方式具有更好的生存率?[J].中华肾脏病杂志,2008,24(12):931-933. 被引量:6
  • 3Kim YL.Update on mechanisms of ultrafiltration failure[J].Petit Dial Int,2009,29 (Suppl 2):S 123-127.
  • 4Yung S,Chan TM.Intrinsic cells:mesothelial cells-central players in regulating inflammation and resolution[J].Petit Dial Int,2009,29 (Suppl 2):S21-27.
  • 5Baur JA,Sinclair DA.Therapeutic potential of resveratrol:the in vivo evidence[J].Nat Rev Drug Discov,2006,5 (6):493-506.
  • 6Nakata R,Takahashi S,Inoue H.Recent advances in the study on resveratrol[J].Biol Pharm Bull,2012,35 (3):273-279.
  • 7Wu J,Yang X,Zhang YF,et al.Glucose-based peritoneal dialysis fluids downregulates TLR and triggers hyporesponsiveness to pathogen-associated molecular patterns in human peritoneal mesothelial cells[J].Clini Vaccine Immunol,2010,17 (5):757-763.
  • 8Collins AJ,Foley RN,Chavers B,et al.United States Renal Data System 2011 Annual Data Report:Atlas of chronic kidney disease & end-stage renal disease in the United States[J].Am J Kidney Dis,2012,59(Suppl 1):A7,el-420.
  • 9Huh JY,Seo EY,Lee HB,et al.Glucose-based peritoneal dialysis solution suppresses adiponectin synthesis through oxidative stress in an experimental model of peritoneal dialysis[J].Perit Dial Int,2012,32 (1):20-28.
  • 10Zhu X,Ling G,Xiao L,et al.Role of mitochondrial respiratory chain complex Ⅲ in high glucose peritoneal dialysate-induced hyperpermeability ofHPMCs[J].RenFail,2010,32(9):1103-1108.

二级参考文献31

  • 1Wright CC, Sim J, Intention-to-treat approach to data from randomized controlled trials: a sensitivity analysis. J Clin Epidemiol, 2003, 56: 833-842.
  • 2Xue JL, Chen SC, Ebben JP, et al. Peritoneal and hemodialysis: Ⅰ. Differences in patient characteristics at initiation. Kidney Int, 2002, 61: 734-740.
  • 3Ganesh SK, Hulbert-Shearon T, Port FK, et al. Mortality differences by dialysis modality among incident ESRD patients with and without coronary artery disease. J Am Soc Nephrol, 2003, 14: 415-424.
  • 4Stack AG, Molony DA, Rahman NS, et al. Impact of dialysis modality on survival of new ESRD patients with congestive heart failure in the United States. Kidney Int, 2003, 64: 1071-1079.
  • 5Lo WK. Peritoneal dialysis utilization and outcome: what are we facing? Perit Dial Int, 2007, 27 Suppl 2: S42-S47.
  • 6Finkelstein FO. Structural requirements for a successful chronic peritoneal dialysis program. Kidney Int Sppul, 2006, (103): S118-S121.
  • 7Burkart J, Piraino B, Kaldas H, et al. Why is the evidence favoring hemodialysis over peritoneal dialysis misleading? Semin Dial, 2007, 20: 200-202.
  • 8U.S. Renal Data System: USRDS 2005 Annual Data Report: Atlas of End- Stage Renal Disease in the United States. Bethesda,MD: National Institutes of Health,National Institute of Diabetes and Digestive and Kidney Disease 2005.
  • 9Sehulman G. Mortality and treatment modality of end-stage renal disease. Ann Intern Med, 2005, 143: 229-231.
  • 10Vonesh EF, Snyder JJ, Foley RN, et al. The differential impact of risk factors on mortality in hemodialysis and peritoneal dialysis. Kidney Int, 2004, 66: 2389-2401.

共引文献5

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部